Currently accepting select investor inquiries — Learn more

HARMONY · The Physics Layer of Biology

Physics-first
drug discovery.

HARMONY is an AI platform built on a new branch of protein physics — one that sees what no other platform can. We are finding drug candidates for cancer, diabetes, and cardiac disease at a speed and accuracy that has never been achieved before.

We are moving fast. We'd like you to move with us.

The tools being used today are blind to what matters most.
We built the tool that sees.

Every major AI drug discovery platform trains on drugs that already exist. HARMONY calculates from first principles — the same way an engineer designs a bridge before pouring concrete, not after it fails.

$157B
Target market today — Oncology and Rare Disease, growing to $350B+ with Agriculture and Industrial
87.4%
Accuracy predicting real clinical drug outcomes across 243 blinded patient cases
93%
Blind prospective accuracy across 149 cancer cases — EGFR, MET, ALK, and RET
36/36
Blind predictions correct across 5 independent peer-reviewed datasets — 100% record

Three of medicine's hardest problems. One platform.

HARMONY does not specialize in one disease. It reads protein physics — and protein physics governs every disease. Here is where we are right now.

Oncology

Cancer

HARMONY identified a single molecular scaffold active across four consecutive nodes of the MAPK cancer pathway — a combination no approved drug currently achieves. This is the kind of breadth pharma partners pay billions to license.

Metabolic

Diabetes

In congenital hyperinsulinism — a rare, life-threatening condition that strikes infants — HARMONY designed a novel drug candidate from protein physics alone. That candidate is now advancing to wet lab validation at Scientist.com.

Cardiac

Heart Disease

HARMONY detects the resistance mechanisms that make cardiac drugs fail — before a molecule is ever synthesized. The cost of missing this in traditional development: $200M and four years, per compound, per miss.

Momentum · July 2026

36/36
Blind predictions correct — time-stamped and cryptographically locked before literature was checked
7
USPTO patent filings confirmed, priority chain dating to August 2025
4
Consecutive cancer pathway targets hit with a single molecular scaffold
3
Known drugs independently re-derived from physics alone — including a 70-year-old FDA medicine

AI powered by physics, not pattern matching.

Most AI drug discovery platforms are sophisticated search engines — they find molecules that look like drugs that already worked. HARMONY is different in kind, not degree. It computes from the laws of physics. That is why it finds molecules that have never existed before.

A Discovery No One Else Has Made

Every protein carries a physical resonance signature that governs how it responds to drugs. InfiniGraph discovered this signature and built the equations to calculate it. No other platform can see it.

Speed That Changes the Economics

HARMONY completes a full protein analysis in 5 seconds at under $50. Traditional drug discovery spends years and hundreds of millions reaching the same starting line HARMONY crosses in a single run.

Built-In Safety

HARMONY cannot produce an unsafe drug candidate. A 50-point safety filter runs inside every generation loop — blocking harmful compounds before they are ever proposed, not after they fail in trials.

A Platform, Not a Pipeline

HARMONY is not a bet on a single drug. It is infrastructure — target-agnostic, indication-agnostic, and designed to power multiple therapeutic programs simultaneously. Every partnership makes the platform stronger.

New results, roughly every two weeks.